InsiderPulseNo transactions found.
No annual data found.
Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Monopar Therapeutics GAAP EPS of -$0.46 beats by $0.36
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans